Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633056 | 1.00 | HTR2A (0.54) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5473376 | 0.94 | HTR2A (0.54) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL25370278 | 0.80 | TAAR1 (0.49) | HTR2ATAAR1HTR2CHTR2B | |
| SCHEMBL2560485 | 0.79 | HTR2A (0.64) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL29417349 | 0.79 | HTR2A (0.64) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL5479509 | 0.72 | HTR2A (0.54) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL26055488 | 0.72 | TAAR1 (0.42) | HTR2ATAAR1 | |
| SCHEMBL398581 | 0.71 | HTR2A (1.00) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL29425260 | 0.71 | HTR2A (1.00) | HTR2ATAAR1HTR1AHTR2CHTR2B | |
| SCHEMBL398580 | 0.71 | HTR2A (1.00) | HTR2ATAAR1HTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630504-B2 | Phenethylamine derivatives, compositions, and methods of use | CYBIN IRL LIMITED (IE) | 2026-05-19 | — | — | US | disclosed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | Park City Bio, LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | KULEON LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-12414936-B2 | Compositions comprising a serotonergic tryptamine compound | CAAMTECH, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | Kuleon, LLC (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4251139-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023156453-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156453-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2023-08-24 | — | — | WO | disclosed |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | Kuleon, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230157997-A9 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20210361679-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210346346-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CAAMTECH, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CNR1, CNR2, HTR5A | HTR2A 6/4885TAAR1 84/4885HTR1A 5/4885 |
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | HTR1A, HTR4, HTR5A | HTR2A 8/4885TAAR1 83/4885HTR1A 1/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | HTR2A 6/4885TAAR1 46/4885HTR1A 5/4885 |
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | HTR5A, HTR1A, HTR3A | HTR2A 5/4885TAAR1 77/4885HTR1A 2/4885 |
| US-12630504-B2 | Phenethylamine derivatives, compositions, and methods of use | HTR2C, HTR1A, HTR2A | HTR2A 3/4885TAAR1 41/4885HTR1A 2/4885 |
| US-20210346346-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | HTR3A, HTR2A, HTR5A | HTR2A 2/4885TAAR1 157/4885HTR1A 5/4885 |
| US-12414936-B2 | Compositions comprising a serotonergic tryptamine compound | HTR3A, HTR2A, HTR5A | HTR2A 2/4885TAAR1 157/4885HTR1A 5/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR2A 19/4885TAAR1 51/4885HTR1A 22/4885 |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | HTR2A, HTR2C, HTR3A | HTR2A 1/4885TAAR1 48/4885HTR1A 4/4885 |
| US-20230157997-A9 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | HTR3A, HTR2A, HTR5A | HTR2A 2/4885TAAR1 157/4885HTR1A 5/4885 |
| US-20210361679-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | HTR3A, HTR2A, HTR5A | HTR2A 2/4885TAAR1 157/4885HTR1A 5/4885 |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | HTR2C, HTR2A, HTR3B | HTR2A 2/4885TAAR1 32/4885HTR1A 9/4885 |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | HTR2A, HTR2C, HTR3A | HTR2A 1/4885TAAR1 48/4885HTR1A 4/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | HTR2A 14/4885TAAR1 77/4885HTR1A 2/4885 |
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | PNMT, HTR2C, HTR2A | HTR2A 3/4885TAAR1 66/4885HTR1A 12/4885 |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | HTR5A, HTR1A, HTR1D | HTR2A 16/4885TAAR1 175/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.